Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

Roche presented promising Alzheimer's data at AAIC, showcasing a comprehensive approach to the disease. Trontinemab's Phase Ib/IIa study demonstrated rapid and robust amyloid plaque clearance, with 91% of participants becoming amyloid PET negative. Adverse events like ARIA-E remained low at under 5%. Phase III trials, TRONTIER 1 and 2, for early symptomatic Alzheimer's are planned to initiate in 2025. Furthermore, Roche announced plans for an additional Phase III trial targeting preclinical Alzheimer's. The Elecsys pTau217 blood test showed potential as a standalone diagnostic, comparable to PET scans for amyloid pathology. This blood test could significantly improve diagnostic accessibility and reduce time to diagnosis. Roche's commitment aims to detect and treat Alzheimer's earlier, potentially slowing or preventing disease progression. The company's extensive research spans investigational medicines and advanced diagnostics. This dual approach targets key drivers of Alzheimer's biology for more effective intervention.